Verastem Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VSTM Nasdaq 8731 https://www.verastem.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Verastem Inc

Verastem Oncology Announces Reverse Stock Split - May 31st, 2023 1:11 pm
Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib - May 25th, 2023 9:05 pm
Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors - May 16th, 2023 11:00 am
Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress - May 9th, 2023 8:05 pm
Strong week for Verastem (NASDAQ:VSTM) shareholders doesn't alleviate pain of five-year loss - May 2nd, 2023 11:45 am
Verastem Oncology to Participate in Upcoming Investor Conferences - May 1st, 2023 11:00 am
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting - Apr 26th, 2023 8:05 pm
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days - Apr 18th, 2023 11:05 am
7 Very Undervalued Penny Stocks to Buy in April 2023 - Apr 6th, 2023 9:39 pm
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 6th, 2023 8:05 pm
New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer - Mar 15th, 2023 11:00 am
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress - Mar 14th, 2023 8:05 pm
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers - Feb 2nd, 2023 12:00 pm
Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock? - Jan 30th, 2023 5:00 pm
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock - Jan 24th, 2023 10:46 pm
Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer - Jan 24th, 2023 10:45 pm
individual investors who own 37% along with institutions invested in Verastem, Inc. (NASDAQ:VSTM) saw increase in their holdings value last week - Jan 11th, 2023 11:24 am
Verastem Oncology Appoints Rob Gagnon to Board of Directors - Dec 15th, 2022 9:30 pm
Verastem Third Quarter 2022 Earnings: US$0.092 loss per share (vs US$0.13 loss in 3Q 2021) - Nov 8th, 2022 1:22 pm
Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress - Nov 3rd, 2022 8:05 pm